Latest / Breaking News To Trading Moves
Yartemlea Approval and the TA-TMA Market Impact Analysis
US FDA approves Omeros drug Yartemlea for TA-TMA (first approved treatment for this dangerous post-transplant complication)
Intro
Welcome back to Breaking News to Trading Moves, where we turn market-moving headlines into long and short trading ideas. Today’s big biotech headline: the FDA approved Omeros’ Yartemlea for TA-TMA, a serious complication that can occur after stem cell transplants.
What happened
The FDA approved Omeros’ drug, branded Yartemlea (narsoplimab-wuug), for adults and children ages 2 and older with transplant-associated thrombotic microangiopathy, or TA-TMA.
Omeros shares…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.